Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Peter Kenemans

Showing results (11-20 of 67) with videos related to

Pageof 7
Sort By:
Maturitas|March 18, 2008
Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapyJohannes Bitzer, Peter Kenemans, Alfred O Mueck, et al.
American Journal of Obstetrics and Gynecology|October 7, 2004
Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its causeJurgen M J Piek, Peter Kenemans, René H M Verheijen
Drugs|February 3, 2006
Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal womenTatjana Elène Vogelvang, Marius Jan van der Mooren, Velja Mijatovic, et al.
Fertility and Sterility|October 10, 2007
Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic reviewMajoie Hemelaar, Marius J van der Mooren, Mandana Rad, et al.
Menopause (New York, N.Y.)|August 19, 2007
Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trialMajoie Hemelaar, Peter Kenemans, C Erik Hack, et al.
Fertility and Sterility|December 14, 2004
HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal womenTatjana E Vogelvang, Velja Mijatovic, Peter Kenemans, et al.
Atherosclerosis|November 7, 2006
Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized studyMarieke O Verhoeven, Majoie Hemelaar, Tom Teerlink, et al.
The American Journal of Cardiology|November 3, 2004
Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal womenTatjana E Vogelvang, Velja Mijatovic, Peter Kenemans, et al.
Menopause (New York, N.Y.)|December 6, 2006
Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal womenMarieke O Verhoeven, Tom Teerlink, Peter Kenemans, et al.
Gynecologic Oncology|August 19, 2007
Ovarian carcinogenesis, an alternative theoryJurgen M J Piek, Peter Kenemans, Ronald P Zweemer, et al.
Pageof 7

Showing results (11-20 of 67) with videos related to

Sort By:
Pageof 7
Maturitas|March 18, 2008
Breast cancer risk in postmenopausal women using testosterone in combination with hormone replacement therapyJohannes Bitzer, Peter Kenemans, Alfred O Mueck, et al.
American Journal of Obstetrics and Gynecology|October 7, 2004
Intraperitoneal serous adenocarcinoma: a critical appraisal of three hypotheses on its causeJurgen M J Piek, Peter Kenemans, René H M Verheijen
Drugs|February 3, 2006
Emerging selective estrogen receptor modulators: special focus on effects on coronary heart disease in postmenopausal womenTatjana Elène Vogelvang, Marius Jan van der Mooren, Velja Mijatovic, et al.
Fertility and Sterility|October 10, 2007
Effects of non-oral postmenopausal hormone therapy on markers of cardiovascular risk: a systematic reviewMajoie Hemelaar, Marius J van der Mooren, Mandana Rad, et al.
Menopause (New York, N.Y.)|August 19, 2007
Hemostatic markers in healthy postmenopausal women during intranasal and oral hormone therapy: a randomized trialMajoie Hemelaar, Peter Kenemans, C Erik Hack, et al.
Fertility and Sterility|December 14, 2004
HMR 3339, a novel selective estrogen receptor modulator, reduces total cholesterol, low-density lipoprotein cholesterol, and homocysteine in healthy postmenopausal womenTatjana E Vogelvang, Velja Mijatovic, Peter Kenemans, et al.
Atherosclerosis|November 7, 2006
Effects of intranasal versus oral hormone therapy on asymmetric dimethylarginine in healthy postmenopausal women: a randomized studyMarieke O Verhoeven, Majoie Hemelaar, Tom Teerlink, et al.
The American Journal of Cardiology|November 3, 2004
Effect of HMR 3339, a novel selective estrogen receptor modulator, on C-reactive protein levels in healthy postmenopausal womenTatjana E Vogelvang, Velja Mijatovic, Peter Kenemans, et al.
Menopause (New York, N.Y.)|December 6, 2006
Effects on asymmetric dimethylarginine of HMR 3339, a novel selective estrogen receptor modulator: a 12-week, randomized, placebo-controlled, double-blind, dose-ranging study in healthy postmenopausal womenMarieke O Verhoeven, Tom Teerlink, Peter Kenemans, et al.
Gynecologic Oncology|August 19, 2007
Ovarian carcinogenesis, an alternative theoryJurgen M J Piek, Peter Kenemans, Ronald P Zweemer, et al.
Pageof 7